619 related articles for article (PubMed ID: 30865922)
1. Management of Immunotherapy-Related Toxicities, Version 1.2019.
Thompson JA; Schneider BJ; Brahmer J; Andrews S; Armand P; Bhatia S; Budde LE; Costa L; Davies M; Dunnington D; Ernstoff MS; Frigault M; Hoffner B; Hoimes CJ; Lacouture M; Locke F; Lunning M; Mohindra NA; Naidoo J; Olszanski AJ; Oluwole O; Patel SP; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wahidi M; Wang Y; Johnson-Chilla A; Scavone JL
J Natl Compr Canc Netw; 2019 Mar; 17(3):255-289. PubMed ID: 30865922
[TBL] [Abstract][Full Text] [Related]
2. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Thompson JA; Schneider BJ; Brahmer J; Achufusi A; Armand P; Berkenstock MK; Bhatia S; Budde LE; Chokshi S; Davies M; Elshoury A; Gesthalter Y; Hegde A; Jain M; Kaffenberger BH; Lechner MG; Li T; Marr A; McGettigan S; McPherson J; Medina T; Mohindra NA; Olszanski AJ; Oluwole O; Patel SP; Patil P; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wang Y; Zaha VG; Lyons M; Dwyer M; Hang L
J Natl Compr Canc Netw; 2022 Apr; 20(4):387-405. PubMed ID: 35390769
[TBL] [Abstract][Full Text] [Related]
3. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
Brahmer JR; Lacchetti C; Thompson JA
J Oncol Pract; 2018 Apr; 14(4):247-249. PubMed ID: 29517954
[No Abstract] [Full Text] [Related]
4. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.
Thompson JA
J Natl Compr Canc Netw; 2018 May; 16(5S):594-596. PubMed ID: 29784734
[TBL] [Abstract][Full Text] [Related]
5. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Thompson JA; Schneider BJ; Brahmer J; Andrews S; Armand P; Bhatia S; Budde LE; Costa L; Davies M; Dunnington D; Ernstoff MS; Frigault M; Kaffenberger BH; Lunning M; McGettigan S; McPherson J; Mohindra NA; Naidoo J; Olszanski AJ; Oluwole O; Patel SP; Pennell N; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wang Y; Weight RM; Johnson-Chilla A; Zuccarino-Catania G; Engh A
J Natl Compr Canc Netw; 2020 Mar; 18(3):230-241. PubMed ID: 32135517
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors].
Wang H; Song P; Si X; Guo X; Li Y; Zhou J; Duan L; Zhang L; Wang M; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):605-614. PubMed ID: 31650941
[TBL] [Abstract][Full Text] [Related]
7. Challenging Cases: Management of Immune-Related Toxicity.
Weber JS
Am Soc Clin Oncol Educ Book; 2018 May; 38():179-183. PubMed ID: 30231403
[TBL] [Abstract][Full Text] [Related]
8. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Brahmer JR; Lacchetti C; Schneider BJ; Atkins MB; Brassil KJ; Caterino JM; Chau I; Ernstoff MS; Gardner JM; Ginex P; Hallmeyer S; Holter Chakrabarty J; Leighl NB; Mammen JS; McDermott DF; Naing A; Nastoupil LJ; Phillips T; Porter LD; Puzanov I; Reichner CA; Santomasso BD; Seigel C; Spira A; Suarez-Almazor ME; Wang Y; Weber JS; Wolchok JD; Thompson JA;
J Clin Oncol; 2018 Jun; 36(17):1714-1768. PubMed ID: 29442540
[TBL] [Abstract][Full Text] [Related]
9. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.
Cortellini A; Buti S; Agostinelli V; Bersanelli M
Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344
[TBL] [Abstract][Full Text] [Related]
10. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.
Cazzaniga ME; Danesi R; Girmenia C; Invernizzi P; Elvevi A; Uguccioni M;
Breast Cancer Res Treat; 2019 Aug; 176(3):483-494. PubMed ID: 31065872
[TBL] [Abstract][Full Text] [Related]
11. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Haanen JBAG; Carbonnel F; Robert C; Kerr KM; Peters S; Larkin J; Jordan K;
Ann Oncol; 2017 Jul; 28(suppl_4):iv119-iv142. PubMed ID: 28881921
[No Abstract] [Full Text] [Related]
12. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Santomasso BD; Nastoupil LJ; Adkins S; Lacchetti C; Schneider BJ; Anadkat M; Atkins MB; Brassil KJ; Caterino JM; Chau I; Davies MJ; Ernstoff MS; Fecher L; Funchain P; Jaiyesimi I; Mammen JS; Naidoo J; Naing A; Phillips T; Porter LD; Reichner CA; Seigel C; Song JM; Spira A; Suarez-Almazor M; Swami U; Thompson JA; Vikas P; Wang Y; Weber JS; Bollin K; Ghosh M
J Clin Oncol; 2021 Dec; 39(35):3978-3992. PubMed ID: 34724386
[TBL] [Abstract][Full Text] [Related]
13. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
Majem M; García-Martínez E; Martinez M; Muñoz-Couselo E; Rodriguez-Abreu D; Alvarez R; Arance A; Berrocal A; de la Cruz-Merino L; Lopez-Martin JA
Clin Transl Oncol; 2020 Feb; 22(2):213-222. PubMed ID: 31993963
[TBL] [Abstract][Full Text] [Related]
14. A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.
Naidoo J; Zhang J; Lipson EJ; Forde PM; Suresh K; Moseley KF; Mehta S; Kwatra SG; Parian AM; Kim AK; Probasco JC; Rouf R; Thorne JE; Shanbhag S; Riemer J; Shah AA; Pardoll DM; Bingham CO; Brahmer JR; Cappelli LC
J Natl Compr Canc Netw; 2019 Jun; 17(6):712-720. PubMed ID: 31200355
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy Toxicities.
Sanchez K; Page DB; Urba W
Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
[TBL] [Abstract][Full Text] [Related]
16. Management of immunotherapy toxicities in older adults.
Bhandari S; Gill AS; Perez CA; Jain D
Semin Oncol; 2018 Aug; 45(4):226-231. PubMed ID: 30446167
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
18. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors.
Hamamoto Y; Shin N; Hoshino T; Kanai T
Future Oncol; 2018 Dec; 14(30):3187-3198. PubMed ID: 30188189
[TBL] [Abstract][Full Text] [Related]
19. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
20. Interprofessional Management of Toxicities Related to Cancer Precision Medicine.
Abueg KD
Semin Oncol Nurs; 2017 Nov; 33(4):376-383. PubMed ID: 28927762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]